Lucid Diagnostics (LUCD)
(Delayed Data from NSDQ)
$0.86 USD
+0.02 (2.41%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $0.85 -0.01 (-1.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
LUCD 0.86 +0.02(2.41%)
Will LUCD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LUCD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LUCD
Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data
LUCD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for LUCD
Lucid Diagnostics Launches New Corporate Website
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuardĀ® Esophageal Precancer Testing in a Screening Population
4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuardĀ® Esophageal Precancer Testing
Buy Rating Affirmed for Lucid Diagnostics Amidst Promising Products and Substantial Market Opportunity
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024